Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7162810 | 1.00 | MEN1 (0.33) | MEN1CYP3A4KMT2ALMNA | |
| SCHEMBL5152849 | 0.85 | LMNA (0.33) | LMNA | |
| SCHEMBL5152844 | 0.85 | LMNA (0.33) | LMNA | |
| SCHEMBL5154320 | 0.76 | LMNA (0.35) | LMNA | |
| SCHEMBL5154317 | 0.76 | LMNA (0.35) | LMNA | |
| SCHEMBL7166506 | 0.75 | MEN1 (0.32) | MEN1CYP3A4KMT2A | |
| SCHEMBL7166510 | 0.75 | MEN1 (0.32) | MEN1CYP3A4KMT2A | |
| SCHEMBL2120406 | 0.71 | MEN1 (0.31) | MEN1CYP3A4KMT2A | |
| SCHEMBL2120404 | 0.71 | MEN1 (0.31) | MEN1CYP3A4KMT2A | |
| SCHEMBL2120902 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0947504-B1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-6555699-B2 | Antitumor and antirheumatic agents, high binding affinity | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-04-29 | — | — | US | disclosed |
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6433200-B1 | ANTITUMOR AND ANTIRHEUMATIC AGENTS, HIGH BINDING AFINITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY | CHUGEI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-08-13 | — | — | US | disclosed |
| US-20020032340-A1 | 16-ene-vitamin D derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-03-14 | — | — | US | disclosed |
| EP-1174424-A1 | 3-METHYLATED VITAMIN D DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-01-23 | — | — | EP | disclosed |
| US-6326503-B1 | ANTITUMOR AGENTS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-1158297-A1 | METHOD FOR SCREENING COMPOUND HAVING AFFINITY FOR VITAMIN D RECEPTOR | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-11-28 | — | — | EP | disclosed |
| US-6184398-B1 | ANTITUMOR AGENTS AND TREATMENT OF RHEUMATIC CONDITIONS; HIGH BINDING ABILITY TO VITAMIN D RECEPTORS AND WEAK HYPERCALCEMIC ACTIVITY; E.G.,1,3-DIHYDROXY-20-3-HYDROXY-3-METHYLBUTYLTHIO)-9,10-SECOPREGNA -5,7,10(19),16-TETRAENE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-02-06 | — | — | US | disclosed |
| EP-0947504-A1 | 16-ENE-VITAMIN D DERIVATIVES | Chugai Seiyaku Kabushiki Kaisha (JP) | 1999-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020193616-A1 | 16-ENE-VITAMIN D DERIVATIVES | VDR, CYP24A1, CYP2R1 | MEN1 721/4885CYP3A4 311/4885KMT2A 4427/4885 |
| US-20020032340-A1 | 16-ene-vitamin D derivatives | VDR, CYP2R1, CYP24A1 | MEN1 1518/4885CYP3A4 95/4885KMT2A 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.